Drug Innovations, Higher Margins and Improving Standards of Clinical Research - Research Report on Quest Diagnostics, Trius, WuXi, Quintiles, and ICON PR Newswire NEW YORK, August 15, 2013 NEW YORK, August 15, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Quest Diagnostics Inc. (NYSE: DGX), Trius Therapeutics, Inc. (NASDAQ: TSRX), WuXi PharmaTech (Cayman) Inc. (NYSE: WX), Quintiles Transnational Holdings Inc. (NYSE: Q), and ICON plc (NASDAQ: ICLR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Quest Diagnostics Inc. Research Report On August 8, 2013, Quest Diagnostics Inc. (Quest Diagnostics) announced that its new genetic test to assist in the delivery of personalized opioid pain-relieving treatment is available. "Genetic testing to personalize the use of pain-alleviating drug therapies is an exciting new clinical field with tremendous potential to promote favorable outcomes for the many millions of individuals struggling with pain," said Charles (Buck) Strom, MD, PhD, Senior Medical Director, Genetics, Quest Diagnostics. Strom added, "The inclusion of Transgenomic's gene discoveries into our genetic testing services will provide physicians with greater insights for safely and effectively administering opioid treatment." According to Quest Diagnostics, it is believed to be the first clinical lab to offer testing for variants in all cytochrome P450 (CYP450) genes known to influence the CYP450 enzyme system, which affects metabolism of opioids and other medications. The Full Research Report on Quest Diagnostics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/05ba_DGX] Trius Therapeutics, Inc. Research Report On August 6, 2013, Trius Therapeutics, Inc. (Trius) reported its Q2 2013 financial results with total revenues of $1.3 million compared to $6.2 million in Q2 2012. Further, the Company reported an increase in net loss to $19.7 million, or $0.41 per diluted share, compared to net loss of $14.4 million, or $0.37 per diluted share, in Q2 2012, and the increase in net loss was primarily attributable to lower collaboration revenues and federal contracts. R&D expenses increased to $14.7 million in Q2 2013 from $16.4 million in Q2 2012 primarily due to lower clinical and development costs for tedizolid phosphate. Further, the Company plans to submit New Drug Applications (NDA) for the oral and intravenous dosage forms of tedizolid phosphate to the US Food and Drug Administration (FDA) in the second half of 2013. The Full Research Report on Trius Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/15b0_TSRX] WuXi PharmaTech (Cayman) Inc. Research Report On August 12, 2013, WuXi PharmaTech Inc. (WuXi) reported its unaudited Q2 2013 financial results with reported net revenue growth of 9.2% YoY to $142.3 million. Net income increased 44.6% YoY to $29.6 million during the quarter. GAAP diluted EPS increased 45.5% YoY to $0.41. "By serving our customers well, we are achieving solid, broad-based revenue growth," said Dr. Ge Li, Chairman and Chief Executive Officer. "We exceeded our second-quarter 2013 revenue guidance, driven by excellent performances by China-based Laboratory Services and Manufacturing Services. We also exceeded our second-quarter 2013 EPS guidance. Year-over-year GAAP diluted EPS growth of 45.5% benefited from this revenue performance, gross margin improvement, large mark-to-market gains from foreign-exchange forward contracts, and lower tax expense." The Company increased its full-year 2013 revenue guidance to $572 million to $578 million and GAAP diluted EPS guidance to $1.38 to $1.44. The Full Research Report on WuXi PharmaTech (Cayman) Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/df7b_WX] Quintiles Transnational Holdings Inc. Research Report On August 1, 2013, Quintiles Transnational Holdings Inc. (Quintiles) reported its Q2 2013 financial results with service revenues declining 0.1% YoY to $944.2 million. Adjusted net income totaled $62.9 million, up 12.6% YoY. Diluted adjusted EPS stood at $0.50, up 6.4% YoY. "Quintiles delivered solid results overall with continued strength in new business wins," said Tom Pike, Quintiles' Chief Executive Officer. I am also pleased to report double-digit adjusted net income growth and improved margins on a year-to-date basis despite the negative impact on revenues that resulted from unfavorable foreign exchange rates." The Company expects its service revenues for 2013 to be in the range of $3.76 billion to $3.81 billion and diluted adjusted EPS to be in the range of $1.95 to $2.05. The Full Research Report on Quintiles Transnational Holdings Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9f5c_Q] ICON plc Research Report On August 7, 2013, ICON Plc, (ICON) announced a collaboration agreement with the National Clinical Trials and Research Centre (NCTRC) to enhance set-up and management of clinical studies in Taiwan. Under the terms of the agreement, both organizations will collaborate on study start-up, site feasibility, key site and investigator selection and patient recruitment as well as improve the standards of clinical research in Taiwan. "We are very pleased to be collaborating with the NCTRC who are at the forefront of clinical research in Taiwan," commented Wei Ming Goh, ICON's Vice President, Asia-Pacific. "By combining the proven expertise of ICON and NCTRC in the region, we can further accelerate study timelines which will benefit our customers and also enhance the Taiwanese clinical trials industry." The Full Research Report on ICON plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/fbb0_ICLR] EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Drug Innovations, Higher Margins and Improving Standards of Clinical Research - Research Report on Quest Diagnostics, Trius,
Press spacebar to pause and continue. Press esc to stop.